Monoamine oxidase inhibitors, commonly called MAOIs, are a class of drugs that block one or both forms of an enzyme called monoamine oxidase, which normally breaks down brain chemicals like serotonin, norepinephrine, and dopamine. The most commonly prescribed MAOIs include phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline (available as a pill or a skin patch called Emsam). Though they were among the very first antidepressants ever discovered, MAOIs remain a small but important part of the treatment landscape, particularly for people whose depression has not responded to newer medications. The drugs come in several distinct subtypes, each with different clinical uses and different levels of dietary hassle, and that distinction matters more than most people realize.
How MAOIs Work
Your body produces an enzyme called monoamine oxidase in two forms, labeled MAO-A and MAO-B. Both sit on the outer membrane of mitochondria inside your cells, where they break down a group of chemical messengers known as monoamines. MAO-A preferentially breaks down serotonin and norepinephrine, while MAO-B is more involved in breaking down dopamine and a trace amine called phenylethylamine.1PubMed Central. Monoamine oxidase inactivation: from pathophysiology to therapeutics When an MAOI blocks one or both of these enzymes, the brain’s supply of those chemical messengers rises. More serotonin and norepinephrine available at nerve synapses is the basis for the antidepressant effect; more dopamine is the basis for the anti-Parkinson effect.
Not all MAOIs do the same thing to the enzyme. Some bind permanently, destroying the enzyme molecule so the body has to build new copies from scratch over the course of about two weeks. Others bind temporarily, letting go after the drug clears the bloodstream. That distinction between irreversible and reversible inhibition has major practical consequences for what you can eat and which other medications are safe to take alongside them.
The Main Categories of MAOIs
MAOIs split into a few groups based on which version of the enzyme they target and whether they lock onto it permanently.
Irreversible, Non-Selective MAOIs
These are the oldest and most potent drugs in the class. They permanently disable both MAO-A and MAO-B. The three used for depression are phenelzine, tranylcypromine, and isocarboxazid. Because they knock out MAO-A in the gut and liver as well as in the brain, they carry the most dietary restrictions. These drugs have shown particular effectiveness in treatment-resistant depression, atypical depression, and bipolar depression.2PubMed. Current place of monoamine oxidase inhibitors in the treatment of depression In head-to-head comparisons, phenelzine and tranylcypromine have been found to outperform older tricyclic antidepressants in outpatients whose depression includes atypical features such as oversleeping, overeating, and heavy sensitivity to rejection.3Neuropsychopharmacology. MAOIs in the Contemporary Treatment of Depression
Selective MAO-B Inhibitors
Selegiline (in oral tablet form, branded Eldepryl or Zelapar) and rasagiline (Azilect) selectively target MAO-B. Because MAO-B handles dopamine more than serotonin, these drugs do not work as standalone antidepressants at their standard oral doses. Instead, they became first-line add-on treatments for Parkinson’s disease, where preserving dopamine is the central goal.4PubMed. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease A newer MAO-B inhibitor, safinamide (Xadago), is reversible rather than permanent. It also modulates glutamate signaling, giving it a dual mechanism that sets it apart from selegiline and rasagiline.5PubMed Central. A dual timeline of safinamide effects in Parkinson’s disease: mechanistic rationale and clinical implications
Reversible Inhibitors of MAO-A (RIMAs)
Moclobemide (Manerix, available in many countries but not the United States) is the best-known example. RIMAs selectively and temporarily block MAO-A, which means the enzyme can still process a surge of tyramine from food if needed. The practical upshot is that dietary restrictions are generally unnecessary during RIMA therapy, and dangerous blood-pressure spikes are rare.6Neuropsychopharmacology. Meta-Analysis of the Reversible Inhibitors of Monoamine Oxidase Type A Moclobemide and Brofaromine for the Treatment of Depression Moclobemide is considered effective for depression, though in practice many clinicians view it as somewhat milder than the irreversible agents.
MAOIs for Depression
Despite being among the oldest antidepressants, MAOIs remain genuinely useful. Their reputation took a hit in the 1960s and 1970s because of the dietary restrictions and because newer, easier-to-prescribe drugs like SSRIs arrived. But for certain patients, particularly those with atypical depression or depression that has not responded to multiple other medications, the irreversible MAOIs consistently perform well. Phenelzine, tranylcypromine, and isocarboxazid have shown broadly comparable effectiveness to one another in outpatient studies.3Neuropsychopharmacology. MAOIs in the Contemporary Treatment of Depression
Atypical depression is a subtype marked by mood reactivity (your mood can lift temporarily in response to positive events), along with symptoms like increased appetite, excessive sleeping, a leaden feeling in the limbs, and acute sensitivity to interpersonal rejection. Many clinicians consider MAOIs the gold-standard treatment for this presentation, even if they are rarely prescribed first due to the monitoring they require.
The reluctance to prescribe MAOIs is a sore spot in psychiatry. Some specialists argue that these drugs are drastically underprescribed because younger physicians were never trained to use them. The dietary restrictions, while real, are more manageable than their reputation suggests, and the clinical payoff in treatment-resistant patients can be substantial.
MAOIs for Parkinson’s Disease
The selective MAO-B inhibitors selegiline and rasagiline play a different role entirely. In Parkinson’s disease, the neurons that produce dopamine gradually die off. By blocking the enzyme that breaks down whatever dopamine remains, MAO-B inhibitors stretch that dwindling supply further. They can be used alone in early Parkinson’s or added to levodopa (the main Parkinson’s drug) in more advanced stages.
In a retrospective study following patients for roughly three years, those who took an MAO-B inhibitor alongside levodopa needed about half the increase in levodopa dosage compared to patients who took levodopa alone. They also had lower rates of dyskinesia, the involuntary movements that are a common and frustrating long-term side effect of levodopa therapy. Selegiline and rasagiline showed equal effectiveness to each other in controlling motor symptoms.7PubMed Central. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study
Beyond simply preserving dopamine, both selegiline and rasagiline appear to have neuroprotective properties. Lab and animal studies suggest they support mitochondrial health, boost the production of antioxidant enzymes, and suppress the toxic clumping of a protein called alpha-synuclein, which is a hallmark of Parkinson’s pathology.8PubMed. Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease Whether this translates to genuinely slowing disease progression in humans remains an open and actively studied question.
The Tyramine Problem and Dietary Restrictions
The most infamous side effect of MAOIs is the so-called “cheese reaction,” a potentially dangerous spike in blood pressure triggered by eating foods rich in tyramine. Tyramine is a natural compound found in aged, fermented, or spoiled foods. Under normal conditions, MAO-A in your gut and liver breaks down tyramine before it reaches the general circulation. When that enzyme is blocked by an irreversible, non-selective MAOI, tyramine passes through unmetabolized and triggers a flood of norepinephrine release. The result can be a sudden, severe spike in blood pressure that causes a throbbing headache at its mildest and can lead to stroke at its worst.9PubMed Central. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
The threshold is surprisingly low. As little as 6 mg of tyramine can produce a mild reaction, and 10 to 25 mg can trigger a severe crisis.10Journal of the American Dietetic Association. Dietary tyramine and other pressor amines in MAOI regimens: A review For perspective, a single serving of aged cheddar can contain well over 10 mg. The foods that pose the greatest risk include aged cheeses, cured or smoked meats, fermented soy products like miso and soy sauce, draft beer, sauerkraut, and any protein-rich food that has been improperly stored. The general advice is to keep tyramine intake below 5 mg per meal and to eat only fresh foods.
The dietary restrictions need to start before or at the same time as the medication and continue for about two to four weeks after stopping it, because the irreversible MAOIs take that long to clear. Your body has to manufacture entirely new MAO enzyme molecules to replace the ones the drug destroyed.
One reason the tyramine issue looms so large in the public imagination is that it was poorly understood in the early decades of MAOI use. Patients were not always warned, and the resulting hypertensive crises gave the drugs a fearsome reputation. Today, with proper guidance and patient education, serious reactions are uncommon. The restriction list is also more nuanced than the blanket “no cheese, no wine” rule that many people have heard. Fresh mozzarella, for instance, is generally safe; aged Parmesan is not. A glass of bottled beer is usually fine; tap beer can be riskier due to residual yeast.
The Transdermal Selegiline Patch
One clever workaround for the dietary restrictions is the selegiline transdermal system, marketed as Emsam. This skin patch delivers selegiline directly into the bloodstream through the skin, bypassing the gut and liver entirely. Because it skips the digestive tract, it avoids significant inhibition of MAO-A in the gut, where the tyramine problem originates.11PubMed Central. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder At its lowest effective dose of 6 mg per 24 hours, the patch eliminates the need for a tyramine-restricted diet altogether.12PubMed. Selegiline transdermal system: current awareness and promise
At the 6 mg dose, selegiline still reaches the brain in sufficient concentrations to inhibit both MAO-A and MAO-B centrally, producing an antidepressant effect. Higher patch doses (9 mg and 12 mg per 24 hours) are available for patients who need more, but at those levels the dietary precautions kick back in, because enough selegiline reaches the gut to inhibit MAO-A there as well. The patch is FDA-approved for major depressive disorder, making it the only MAOI formulation that can be used without dietary monitoring at its starting dose.
Dangerous Drug Interactions
The dietary restrictions get most of the attention, but the drug interactions with MAOIs are arguably more dangerous and more clinically relevant. The most serious concern is serotonin syndrome, a potentially fatal condition caused by too much serotonin activity in the brain. It can produce agitation, high fever, muscle rigidity, seizures, and in extreme cases death. The combination of an MAOI, especially one that inhibits MAO-A, with any drug that raises serotonin levels is the most dangerous pairing.13PubMed Central. Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions
The list of drugs that can trigger serotonin syndrome when combined with an MAOI is long and includes some that people might not expect. SSRIs like fluoxetine (Prozac) and sertraline (Zoloft) are the most obvious. But the list also extends to certain pain medications (meperidine, tramadol, and the cough suppressant dextromethorphan found in many over-the-counter cold medicines), the herbal supplement St. John’s wort, and the antibiotic linezolid, which itself has MAOI properties.
The risk with selective MAO-B inhibitors like selegiline and rasagiline is a subject of some debate. While prescribing guidelines warn against combining them with SSRIs, the actual evidence is thinner than the warning implies. A large retrospective study of over 1,500 Parkinson’s patients found no cases of serotonin syndrome when rasagiline was given alongside an SSRI. A separate survey identified 11 potential cases among 4,568 patients taking selegiline with antidepressants, along with 17 published case reports across both drugs.14PubMed Central. Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors The risk appears low but not zero, and many neurologists cautiously co-prescribe these combinations while monitoring closely.
Switching between an MAOI and another antidepressant also requires a washout period, typically two weeks for most MAOIs and five weeks when switching from fluoxetine (which has a very long-lasting metabolite) to an MAOI. Ignoring the washout can produce the same dangerous serotonin overload.
Common Side Effects Beyond Tyramine Reactions
Even when the diet is followed perfectly, MAOIs carry a distinct side-effect profile. The irreversible agents commonly cause orthostatic hypotension, a drop in blood pressure when you stand up that can produce dizziness or fainting. This is often the most bothersome day-to-day side effect and is dose-related. Other frequent complaints include insomnia (particularly with tranylcypromine, which has a mild stimulant quality), weight gain (particularly with phenelzine), sexual dysfunction, and peripheral edema or swelling in the ankles.
In overdose, MAOIs produce a triad of clinical toxicity patterns: acute poisoning from the overdose itself, serotonin syndrome if serotonergic drugs are also on board, and hypertensive crisis. The acute toxicity results from a massive release of stored monoamines from neurons and can include dangerously high fever, cardiovascular collapse, and multi-organ failure. MAOI overdoses are considered medical emergencies and are more difficult to manage than overdoses of most other antidepressants, which is one reason these drugs are prescribed cautiously in patients at risk of self-harm.
How MAOIs Were Discovered
The story of MAOIs is one of the great accidental discoveries in medicine. In the early 1950s, iproniazid was being tested as a treatment for tuberculosis. Clinicians noticed that TB patients given iproniazid became unexpectedly cheerful, to the point of dancing in the hospital wards, according to contemporary accounts. Researchers traced this mood-lifting effect to the drug’s inhibition of monoamine oxidase, and by the late 1950s iproniazid was repurposed as the first antidepressant.15PubMed. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today This discovery was partly serendipitous: iproniazid was not designed as a psychiatric drug, and its antidepressant properties only became obvious through clinical observation.16PubMed Central. Role of serendipity in the discovery of classical antidepressant drugs: Applying operational criteria and patterns of discovery
Iproniazid was eventually withdrawn due to liver toxicity, but it spawned the entire class. Phenelzine, tranylcypromine, and isocarboxazid followed as safer irreversible inhibitors. Decades later, the development of selective and reversible variants expanded the class into Parkinson’s treatment and reduced, though never eliminated, the dietary burden.
Off-Label Uses
MAOIs have been explored for a handful of conditions beyond depression and Parkinson’s. Phenelzine has shown promise as a migraine preventive. In a controlled study of adults with migraine, phenelzine produced a large reduction in both the frequency and severity of attacks. The same study found that combining phenelzine with a beta-blocker was safe and reduced the side effects associated with either drug alone.17Elsevier / Biological Psychiatry. Phenelzine and atenolol in migraine Social anxiety disorder is another area where phenelzine has performed well in clinical trials, though it is rarely used for this purpose now that SSRIs are available.
Some clinicians have also used MAOIs for panic disorder, post-traumatic stress disorder, and certain chronic pain conditions, though the evidence base for these uses is smaller and less consistent than for depression. The practical hurdles of dietary monitoring and drug interactions mean that off-label use tends to be reserved for patients who have exhausted other options.
Why MAOIs Are Still Worth Knowing About
If you or someone you know is dealing with depression that has not responded to first-line treatments, MAOIs are worth discussing with a psychiatrist. Many people go through multiple rounds of SSRIs, SNRIs, and atypical antidepressants before anyone raises the possibility of an MAOI, and some clinicians never raise it at all. The dietary restrictions are a genuine inconvenience, not a trivial one, but they are manageable for a motivated patient. The transdermal selegiline patch sidesteps the tyramine issue entirely at its starting dose, making it an accessible entry point for people who are wary of the diet.
For Parkinson’s patients, the MAO-B inhibitors selegiline, rasagiline, and safinamide are standard parts of the treatment toolkit. They are not a cure, but they can delay the need to increase levodopa, reduce motor complications, and possibly offer neuroprotective benefits that go beyond symptom management. The choice between them often comes down to individual tolerance and whether a reversible inhibitor like safinamide offers advantages for a particular patient’s medication regimen.